A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)(COMPLETED)
This study has been completed.
Information provided by:
First received: September 22, 2004
Last updated: May 21, 2013
Last verified: May 2013
The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of osteoarthritis of the knee.
Drug: MK0966, rofecoxib
Drug: Comparator: celecoxib, placebo
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||A Randomized, Placebo-Controlled, Parallel-Group, Double -Blind Study to Evaluate the Safety and Efficacy of Rofecoxib 12.5 mg and Celecoxib 200 mg in Patients With Osteoarthritis of the Knee|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Merck:
Primary Outcome Measures:
- Osteoarthritis (OA) of the knee as measured by Patient Global Assessment of Response to Therapy (PGART) and WOMAC VA 3.0 over 6 weeks of treatment.
Secondary Outcome Measures:
- OA of the knee as measured by PGART over 6 wks of treatment.
- WOMAC Question #1 over 6 wks of treatment.
|Study Start Date:||May 2003|
|Primary Completion Date:||December 2003 (Final data collection date for primary outcome measure)|
The duration of treatment is 6 weeks.
Contacts and Locations